Baker Bros. Advisors LP Albireo Pharma, Inc. Transaction History

Baker Bros. Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $2.5 Million - $3.53 Million	-104,521 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $6.53 Million - $9.64 Million	-307,945 Reduced 74.66%	104,521 $2.43 Million
Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $4.31 Million - $5.76 Million	-136,581 Reduced 24.88%	412,466 $15.5 Million
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $4.17 Million - $7.49 Million	180,000 Added 48.77%	549,047 $18.3 Million
Q1 2020 May 15, 2020	BUY	$11.67 - $27.23 $1.39 Million - $3.24 Million	119,047 Added 47.62%	369,047 $6.04 Million
Q1 2018 May 15, 2018	BUY	$26.78 - $39.35 $1.34 Million - $1.97 Million	50,000 Added 25.0%	250,000 $8.14 Million
Q3 2017 Nov 14, 2017	BUY	$20.44 - $25.65 $4.09 Million - $5.13 Million	200,000	200,000 $4.19 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.